Don’t fall for companies that claim their conjugate is unique/different. Yeah it might make a difference but it isn’t nearly as important as the target.
I would argue that the reverse might be true—i.e. that the targets for applying ADCs tend to be pretty well know, but the different linker technologies can make a big difference in safety.
Better safety allows higher dosing, which in turn increases efficacy. ADCs are essentially chemotherapy agents with a twist that enables higher dosing without the concomitant toxicity. There are many cancer indications where traditional chemo remains the SoC that ought to be ripe for penetration by ADCs.
p.s. I do not own any ADC companies directly, but I’m long PFE (SGEN).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.